Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Cirrhosis
  Free Subscription

Articles published in
J Hepatol
    May 2026
  1. KRAG A, Tacke F, Israelsen M, Younossi ZM, et al
    Is liver steatosis a disease or the emperor's new clothes?
    J Hepatol. 2026;84:993-1001.
    >> Share

    April 2026
  2. AGUILAR F, Lozano JJ, Claria J, Reinartz Groba SN, et al
    Corrigendum to "Maladaptive emergency granulopoiesis predicts poor outcomes in patients hospitalized with decompensated cirrhosis" [J Hepatol (2026) 749-765].
    J Hepatol. 2026 Apr 22:S0168-8278(26)00156-X. doi: 10.1016/j.jhep.2026.
    >> Share

  3. LACKNER C, Gouw ASH, Avancini Ferreira Alves V, Arola J, et al
    Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials.
    J Hepatol. 2026;84:693-701.
    >> Share

    March 2026
  4. ZENG J, Gao Z, Jiang Y, Dai Z, et al
    Early Abstinence, Socioeconomic Barriers, and Survival in Decompensated Alcohol-Related Cirrhosis: A Real-World Cohort from China.
    J Hepatol. 2026 Mar 26:S0168-8278(26)00153-4. doi: 10.1016/j.jhep.2026.
    >> Share

  5. BALLESTER MP, Gallego-Duran R, Shalimar, Thomsen KL, et al
    Ammonia measurement in cirrhosis: International Delphi consensus recommendations from ISHEN.
    J Hepatol. 2026 Mar 20:S0168-8278(26)00146-7. doi: 10.1016/j.jhep.2026.
    >> Share

  6. LUUKKONEN PK
    Targeting metabolism to modify cirrhosis: Lessons from FGF21 therapy in MASH.
    J Hepatol. 2026 Mar 19:S0168-8278(26)00131-5. doi: 10.1016/j.jhep.2026.
    >> Share

  7. STERN C, Loustaud-Ratti V, Yurdaydin C, Brancaccio G, et al
    Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program.
    J Hepatol. 2026;84:531-542.
    >> Share

  8. EL-SERAG HB, Lopez C, Luster M, Reddy KR, et al
    HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort.
    J Hepatol. 2026;84:578-586.
    >> Share

  9. VILAR-GOMEZ E, Yates KP, Kleiner DE, Behling C, et al
    Genetic and non-genetic drivers of histological progression and regression in MASLD.
    J Hepatol. 2026;84:502-516.
    >> Share

    February 2026
  10. TELLEZ L, Donate J, Albillos A
    Early portopulmonary hypertension: a signal of increased mortality risk in cirrhosis.
    J Hepatol. 2026 Feb 17:S0168-8278(26)00074-7. doi: 10.1016/j.jhep.2026.
    >> Share

  11. CAI J, Yip TC, Wong GL, Zhang Y, et al
    Global epidemiology of bacterial infections in patients with cirrhosis: a systematic review and meta-analysis.
    J Hepatol. 2026 Feb 16:S0168-8278(26)00071-1. doi: 10.1016/j.jhep.2026.
    >> Share

  12. ZHOU XD, Lian LY, Chen QF, Kim SU, et al
    Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD.
    J Hepatol. 2026;84:254-265.
    >> Share

    January 2026
  13. HOFER BS, Tonon M, Buttler L, Camoes Neves J, et al
    Incidence and implications of abstinence-induced recompensation in alcohol-related cirrhosis.
    J Hepatol. 2026 Jan 22:S0168-8278(26)00018-8. doi: 10.1016/j.jhep.2026.
    >> Share

  14. LUO X, Xiang Z, Yang Z
    Emergency granulopoiesis in decompensated cirrhosis: mechanistic and therapeutic considerations.
    J Hepatol. 2026 Jan 9:S0168-8278(26)00005-X. doi: 10.1016/j.jhep.2025.
    >> Share

  15. XU D, Zhang Z, Zhu Z, Wei W, et al
    Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels.
    J Hepatol. 2026;84:165-180.
    >> Share

    December 2025
  16. CHEN J, Yang S, Xu X, Shi Y, et al
    Emergency granulopoiesis-linked module activation in PBMC transcriptomes associates with adverse outcomes in HBV-related cirrhosis with acute decompensation.
    J Hepatol. 2025 Dec 19:S0168-8278(25)02730-8. doi: 10.1016/j.jhep.2025.
    >> Share

  17. PENNISI G, Di Maria G, Wong VW, de Ledinghen V, et al
    Impact of first and further decompensation in patients with compensated ACLD due to MASLD.
    J Hepatol. 2025;83:1266-1277.
    >> Share

    November 2025
  18. AGUILAR F, Lozano JJ, Claria J, Reinartz Groba SN, et al
    Maladaptive emergency granulopoiesis predicts poor outcomes in patients hospitalized with decompensated cirrhosis.
    J Hepatol. 2025 Nov 26:S0168-8278(25)02630-3. doi: 10.1016/j.jhep.2025.
    >> Share

  19. LI R, Zhang J, Peng J, Zhang J, et al
    Divergent sex-specific trends in alcohol-attributable cirrhosis and liver cancer mortality: population-level insights complementing NHANES findings.
    J Hepatol. 2025 Nov 14:S0168-8278(25)02623-6. doi: 10.1016/j.jhep.2025.
    >> Share

    October 2025
  20. TELLEZ L, Donate J, Guerrero A, Beraza IA, et al
    Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort.
    J Hepatol. 2025 Oct 9:S0168-8278(25)02490-0. doi: 10.1016/j.jhep.2025.
    >> Share

  21. THEVENOT T, Desmarets M, Tio G
    Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in patients with severe cirrhosis and ascites, not the end of the story?
    J Hepatol. 2025 Oct 9:S0168-8278(25)02551-6. doi: 10.1016/j.jhep.2025.
    >> Share

  22. GARG P, Verma N, Jalan R
    Reply to: RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
    J Hepatol. 2025 Oct 9:S0168-8278(25)02549-8. doi: 10.1016/j.jhep.2025.
    >> Share

  23. RUDLER M
    Preemptive TIPS in patients with cirrhosis and acute variceal bleeding related to gastric varices: The GAVAPROSEC trial.
    J Hepatol. 2025 Oct 6:S0168-8278(25)02476-6. doi: 10.1016/j.jhep.2025.
    >> Share

  24. WONG YJ, Lam L, Soret PA, Lemoinne S, et al
    Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.
    J Hepatol. 2025 Oct 3:S0168-8278(25)02519-X. doi: 10.1016/j.jhep.2025.
    >> Share

  25. OCHOA-ALLEMANT P, Hubbard RA, Kaplan DE, Serper M, et al
    Cause-specific mortality in patients with steatotic liver disease in the United States.
    J Hepatol. 2025;83:860-869.
    >> Share

  26. DIAZ LA, Alazawi W, Agrawal S, Arab JP, et al
    High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.
    J Hepatol. 2025;83:849-859.
    >> Share

    September 2025
  27. HIRSCHFIELD GM, Kowdley KV, Trivedi PJ, Eksteen B, et al
    Phase II INTEGRIS-PSC trial of bexotegrast, an alphavbeta6/alphavbeta1 integrin inhibitor, in primary sclerosing cholangitis.
    J Hepatol. 2025 Sep 26:S0168-8278(25)02498-5. doi: 10.1016/j.jhep.2025.
    >> Share

  28. LISMAN T, Puente A, Garcia-Pagan JC
    Anticoagulant therapy to delay disease progression in patients with cirrhosis - reponse to Acka et al., Bot et al. and Feng et al.
    J Hepatol. 2025 Sep 25:S0168-8278(25)02495-X. doi: 10.1016/j.jhep.2025.
    >> Share

  29. VERMA N, Kaur P, Garg P, Ranjan V, et al
    Corrigendum to "Clinical and pathophysiological characteristics of non-acute decompensation of cirrhosis" [J Hepatol (2025) https://doi.org/10.1016/j.jhep.2025.02.028].
    J Hepatol. 2025 Sep 25:S0168-8278(25)02475-4. doi: 10.1016/j.jhep.2025.
    >> Share

  30. ZHANG T
    RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
    J Hepatol. 2025 Sep 24:S0168-8278(25)02499-7. doi: 10.1016/j.jhep.2025.
    >> Share

  31. AKCA M, Ketenci YB, Demiroz H, Avcioglu U, et al
    Concerns on Rivaroxaban Use in Cirrhosis: Pharmacokinetic, Safety, and Bleeding Risk Considerations.
    J Hepatol. 2025 Sep 17:S0168-8278(25)02489-4. doi: 10.1016/j.jhep.2025.
    >> Share

  32. FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
    Erratum to 'Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis' [J Hepatol 83 (2025) 70-80].
    J Hepatol. 2025 Sep 5:S0168-8278(25)02439-0. doi: 10.1016/j.jhep.2025.
    >> Share

  33. NEUSCHWANDER-TETRI BA, Akbary K, Carpenter DH, Noureddin M, et al
    The emerging role of second harmonic generation/two photon excitation for precision digital analysis of liver fibrosis in MASH clinical trials.
    J Hepatol. 2025;83:790-799.
    >> Share

    August 2025
  34. VERMA N, Kaur P, Jalan R
    Disease Staging and Clinical State in Cirrhosis: Is severity, acuity and pathophysiology the missing link?
    J Hepatol. 2025 Aug 25:S0168-8278(25)02456-0. doi: 10.1016/j.jhep.2025.
    >> Share

  35. ROMERO-CRISTOBAL M
    Cirrhosis recompensation: what it is and what it ought to be - insights from the philosophy of science.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02449-3. doi: 10.1016/j.jhep.2025.
    >> Share

  36. RIDOLA L, Riggio O
    Rifaximin and Survival in Cirrhosis: An Unmet Clinical Promise.
    J Hepatol. 2025 Aug 20:S0168-8278(25)02446-8. doi: 10.1016/j.jhep.2025.
    >> Share

  37. VERMA N, Garg P, Kaur P, Munjal S, et al
    Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acutely decompensated cirrhosis.
    J Hepatol. 2025 Aug 12:S0168-8278(25)02405-5. doi: 10.1016/j.jhep.2025.
    >> Share

  38. PIANO S, Patidar KR, Juanola A
    Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: enough, but not too much.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02395-5. doi: 10.1016/j.jhep.2025.
    >> Share

  39. BJORN AB, Jensen MD, Pero A, Villadsen GE, et al
    Male-to-female ratios in the risk of hepatocellular carcinoma: A nationwide study of Danish patients with viral or non-viral cirrhosis.
    J Hepatol. 2025 Aug 2:S0168-8278(25)02390-6. doi: 10.1016/j.jhep.2025.
    >> Share

  40. HARRISON SA, Alkhouri N, Ortiz-Lasanta G, Rudraraju M, et al
    A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
    J Hepatol. 2025;83:293-303.
    >> Share

  41. STURM L, Schultheiss M, Stohr F, Labenz C, et al
    Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPS.
    J Hepatol. 2025;83:348-357.
    >> Share

  42. YIP TC, Lee HW, Lin H, Tsochatzis E, et al
    Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2025;83:304-314.
    >> Share

  43. VERMA N, Angeli P, Jalan R
    Stratification, Therapeutic Targeting and Towards Personalised Care in Cirrhosis.
    J Hepatol. 2025 Aug 1:S0168-8278(25)02378-5. doi: 10.1016/j.jhep.2025.
    >> Share

    July 2025
  44. RUDLER M
    Simvastatin and rifaximin in patients with decompensated cirrhosis: Still a place for LIVER HOPE?
    J Hepatol. 2025 Jul 30:S0168-8278(25)02323-2. doi: 10.1016/j.jhep.2025.
    >> Share

  45. PUENTE A, Turon F, Martinez J, Fortea JI, et al
    Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study.
    J Hepatol. 2025 Jul 19:S0168-8278(25)02336-0. doi: 10.1016/j.jhep.2025.
    >> Share

  46. PU X, Liu Y, Lyu Z, Zhou Y, et al
    B cells drive CCR5(+)CD4(+) tissue-resident memory T cell cytotoxicity via IL-15Ralpha-IL-15 signaling in primary biliary cholangitis.
    J Hepatol. 2025 Jul 17:S0168-8278(25)02340-2. doi: 10.1016/j.jhep.2025.
    >> Share

  47. ENGEL B, Alaswad A, Campos-Murguia A, Zoodsma M, et al
    Molecular signatures discriminating different types of rejection in human liver transplants.
    J Hepatol. 2025 Jul 14:S0168-8278(25)02338-4. doi: 10.1016/j.jhep.2025.
    >> Share

  48. THEVENOT T, Elkrief L, Bureau C, Bardou-Jacquet E, et al
    Effect of rifaximin in patients with severe cirrhosis and ascites: A randomized double-blind placebo-controlled clinical trial.
    J Hepatol. 2025 Jul 11:S0168-8278(25)02318-9. doi: 10.1016/j.jhep.2025.
    >> Share


  49. EASL Clinical Practice Guidelines on TIPS.
    J Hepatol. 2025;83:177-210.
    >> Share

  50. DE ZAWADZKI A, Leeming DJ, Sanyal AJ, Anstee QM, et al
    Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.
    J Hepatol. 2025;83:239-257.
    >> Share

  51. POSE E, Piano S, Thiele M, Fabrellas N, et al
    Moving diagnosis of liver fibrosis into the community.
    J Hepatol. 2025;83:258-270.
    >> Share

  52. WALLACE C, Gamkrelidze I, Estes C, Razavi H, et al
    Modeling the health and economic impact of pharmacologic therapies for MASLD in the United States.
    J Hepatol. 2025;83:21-30.
    >> Share

  53. ALLEN AM, Kamath PS
    Staging decompensated cirrhosis: Lumping, splitting, or just rearranging the deck chairs on the Titanic?
    J Hepatol. 2025 Jul 1:S0168-8278(25)02198-1. doi: 10.1016/j.jhep.2025.
    >> Share

    May 2025
  54. RUDLER M
    Autologous macrophage therapy for compensated cirrhosis, some hope at the horizon.
    J Hepatol. 2025 May 23:S0168-8278(25)00248-X. doi: 10.1016/j.jhep.2025.
    >> Share


  55. EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.
    J Hepatol. 2025 May 10:S0168-8278(25)00173-4. doi: 10.1016/j.jhep.2025.
    >> Share


  56. EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease.
    J Hepatol. 2025 May 8:S0168-8278(25)00235-1. doi: 10.1016/j.jhep.2025.
    >> Share

  57. LEVY C, Abouda GF, Bilir BM, Bonder A, et al
    Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
    J Hepatol. 2025 May 8:S0168-8278(25)00252-1. doi: 10.1016/j.jhep.2025.
    >> Share

  58. CHRISTAKI M, Biros D, Tsiakas I, Milionis H, et al
    Carvedilol is superior to propranolol in preventing first and further decompensation, and mortality in patients with cirrhosis.
    J Hepatol. 2025 May 7:S0168-8278(25)00291-0. doi: 10.1016/j.jhep.2025.
    >> Share

  59. CALES P, Canivet CM, Costentin C, Lannes A, et al
    A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD.
    J Hepatol. 2025;82:794-804.
    >> Share

  60. ABDURRACHIM D, Lek S, Ong CZL, Wong CK, et al
    Utility of AI digital pathology as an aid for pathologists scoring fibrosis in MASH.
    J Hepatol. 2025;82:898-908.
    >> Share

    April 2025
  61. REIBERGER T, Maasoumy B
    Advancing our understanding of recompensated cirrhosis - the new "holy grail" of decompensated cirrhosis.
    J Hepatol. 2025 Apr 16:S0168-8278(25)00241-7. doi: 10.1016/j.jhep.2025.
    >> Share

  62. TONON M, Gagliardi R, Pompili E, Barone A, et al
    Validation and expansion of Baveno VII recompensation criteria in patients with cirrhosis and curable liver disease.
    J Hepatol. 2025 Apr 12:S0168-8278(25)00245-4. doi: 10.1016/j.jhep.2025.
    >> Share

  63. NAIK I, Yeo YH, Ng WH, Sheng-Kai Ma K, et al
    Carvedilol is Associated with Lower Risk of Hepatic Decompensation Compared to Other Non-Selective Beta-Blockers in Cirrhosis.
    J Hepatol. 2025 Apr 11:S0168-8278(25)00232-6. doi: 10.1016/j.jhep.2025.
    >> Share

  64. SUN SS, Zhang J, Jin YP, Li L, et al
    A Rare Cause of Lipid Metabolism Disorder and Cirrhosis in an Adult.
    J Hepatol. 2025 Apr 9:S0168-8278(25)00227-2. doi: 10.1016/j.jhep.2025.
    >> Share

    March 2025
  65. SCHLEICHER EM, Karbannek H, Weinmann-Menke J, Galle PR, et al
    Effect of albumin treatment duration on response rates and outcomes in patients with cirrhosis and acute kidney injury.
    J Hepatol. 2025 Mar 19:S0168-8278(25)00164-3. doi: 10.1016/j.jhep.2025.
    >> Share

  66. LANTINGA MA, Tapper EB, Drenth JPH
    Reply: Revisiting the use of albumin in patients with cirrhosis - trial design matters.
    J Hepatol. 2025 Mar 12:S0168-8278(25)00161-8. doi: 10.1016/j.jhep.2025.
    >> Share

  67. VERMA N, Kaur P, Garg P, Ranjan V, et al
    Clinical and Pathophysiological Characteristics of Non-acute Decompensation of Cirrhosis.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00137-0. doi: 10.1016/j.jhep.2025.
    >> Share

  68. SANCHEZ-TORRIJOS Y, Fernandez-Alvarez P, Rosales JM, Perez-Estrada C, et al
    Recompensation of decompensated cirrhosis in hepatitis C patients after SVR: Prognostic implications.
    J Hepatol. 2025 Mar 6:S0168-8278(25)00153-9. doi: 10.1016/j.jhep.2025.
    >> Share

  69. TELLEZ L, Rincon D, Payance A, Jaillais A, et al
    Non-invasive assessment of severe liver fibrosis in patients with Fontan-associated liver disease: The VALDIG-EASL FONLIVER cohort.
    J Hepatol. 2025;82:480-489.
    >> Share

  70. ZHONG Q, Zhou R, Huang YN, Huang RD, et al
    Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.
    J Hepatol. 2025;82:427-437.
    >> Share

    February 2025
  71. NAHON P, Lusivika-Nzinga C, Merle P, Zoulim F, et al
    Value of non-invasive test dynamics in guiding HCC surveillance decisions after HCV cure in patients with cirrhosis.
    J Hepatol. 2025 Feb 26:S0168-8278(25)00084-4. doi: 10.1016/j.jhep.2025.
    >> Share

  72. LOHSE AW, Kamath PS, Sarin SK
    The complexity of portal hypertension without (apparent) cirrhosis.
    J Hepatol. 2025 Feb 19:S0168-8278(25)00088-1. doi: 10.1016/j.jhep.2025.
    >> Share

  73. ZANETTO A, Campello E, Senzolo M, Simioni P, et al
    Response to: "Procedural bleeding in patients with cirrhosis: from prediction towards prevention".
    J Hepatol. 2025 Feb 19:S0168-8278(25)00087-X. doi: 10.1016/j.jhep.2025.
    >> Share

  74. MA AT, Juanola A, Sole C, Gines P, et al
    Revisiting the use of albumin in patients with cirrhosis - trial design matters.
    J Hepatol. 2025 Feb 19:S0168-8278(25)00086-8. doi: 10.1016/j.jhep.2025.
    >> Share

  75. MARTI-AGUADO D, Calleja JL, Bataller R, Crespo J, et al
    Reply to: "The HDL criterion for MetALD can misclassify patients with cirrhosis".
    J Hepatol. 2025 Feb 4:S0168-8278(25)00057-1. doi: 10.1016/j.jhep.2025.
    >> Share

  76. XUE X, Liu R, Cai Y, Gong L, et al
    Hyodeoxycholic acid ameliorates cholestatic liver fibrosis by facilitating m(6)A-regulated expression of a novel anti-fibrotic target ETV4.
    J Hepatol. 2025 Feb 4:S0168-8278(25)00055-8. doi: 10.1016/j.jhep.2025.
    >> Share

  77. MARKOVIC J, Li R, Khanal R, Peng Q, et al
    Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis.
    J Hepatol. 2025;82:301-314.
    >> Share

  78. LIU YJ, Kimura M, Li X, Sulc J, et al
    ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.
    J Hepatol. 2025;82:174-188.
    >> Share

    January 2025
  79. LISMAN T
    Procedural bleeding in patients with cirrhosis: from prediction towards prevention.
    J Hepatol. 2025 Jan 11:S0168-8278(25)00010-8. doi: 10.1016/j.jhep.2025.
    >> Share

  80. RUDLER M
    Primary prophylaxis of acute variceal bleeding in patients with severe cirrhosis: Time for combination therapy?
    J Hepatol. 2025 Jan 11:S0168-8278(24)02773-9. doi: 10.1016/j.jhep.2024.
    >> Share

  81. GENG A, Brenig RG, Roux J, Lutge M, et al
    Circulating monocytes upregulate CD52 and sustain innate immune function in cirrhosis unless acute decompensation emerges.
    J Hepatol. 2025 Jan 10:S0168-8278(24)02818-6. doi: 10.1016/j.jhep.2024.
    >> Share

  82. BAJAJ JS, Fagan A, Gavis EA, Sterling RK, et al
    Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.
    J Hepatol. 2025 Jan 10:S0168-8278(25)00005-4. doi: 10.1016/j.jhep.2024.
    >> Share

  83. DEGASPERI E, Anolli MP, Jachs M, Reiberger T, et al
    Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis.
    J Hepatol. 2025 Jan 8:S0168-8278(25)00001-7. doi: 10.1016/j.jhep.2024.
    >> Share

  84. CROUCHET E, Dachraoui M, Juhling F, Roehlen N, et al
    Targeting the liver clock improves fibrosis by restoring TGF-beta signaling.
    J Hepatol. 2025;82:120-133.
    >> Share

  85. KRENDL FJ, Cardini B, Zoller H, Schneeberger S, et al
    Leveraging normothermic liver machine perfusion as a platform for oncologic assessment in cirrhotic livers.
    J Hepatol. 2025;82:e12-e14.
    >> Share

    December 2024
  86. IM GY, Bibireddy A, Rath S
    The HDL criterion for MetALD can misclassify patients with cirrhosis.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02781-8. doi: 10.1016/j.jhep.2024.
    >> Share

  87. FORTEA JI, Alvarado-Tapias E, Simbrunner B, Ezcurra I, et al
    Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis.
    J Hepatol. 2024 Dec 17:S0168-8278(24)02772-7. doi: 10.1016/j.jhep.2024.
    >> Share

  88. ENGELMANN C
    Rifaximin in cirrhosis: Is its microbiological spotless record under threat?
    J Hepatol. 2024 Dec 16:S0168-8278(24)02735-1. doi: 10.1016/j.jhep.2024.
    >> Share

  89. ZANETTO A, Campello E, Bulato C, Willems R, et al
    Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis.
    J Hepatol. 2024 Dec 11:S0168-8278(24)02762-4. doi: 10.1016/j.jhep.2024.
    >> Share

  90. MARTI-AGUADO D, Calleja JL, Vilar-Gomez E, Iruzubieta P, et al
    Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024;81:930-940.
    >> Share

    November 2024
  91. CHE-TO LAI J, Wong GL, Tse YK, Hui VW, et al
    Histological severity, clinical outcomes and impact of antiviral treatment in indeterminate phase of chronic hepatitis B: a systematic review and meta-analysis.
    J Hepatol. 2024 Nov 20:S0168-8278(24)02718-1. doi: 10.1016/j.jhep.2024.
    >> Share

  92. VANDERSCHUEREN E, Wim Laleman
    Non-invasive algorithms could outperform HVPG in selecting candidates for non-selective beta-blockers in cirrhosis.
    J Hepatol. 2024 Nov 13:S0168-8278(24)02711-9. doi: 10.1016/j.jhep.2024.
    >> Share

  93. HUR MH, Lee JH
    Reply to "A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?".
    J Hepatol. 2024 Nov 8:S0168-8278(24)02700-4. doi: 10.1016/j.jhep.2024.
    >> Share

  94. KIM HY, Rosenthal SB, Liu X, Miciano C, et al
    Multi-Modal Analysis of human Hepatic Stellate Cells identifies novel therapeutic targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Hepatol. 2024 Nov 8:S0168-8278(24)02667-9. doi: 10.1016/j.jhep.2024.
    >> Share

  95. HARRISON SA, Dubourg J
    Liver biopsy evaluation in MASH drug development: Think thrice, act wise.
    J Hepatol. 2024;81:886-894.
    >> Share

  96. OH JH, Ahn SB, Cho S, Nah EH, et al
    Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.
    J Hepatol. 2024;81:772-780.
    >> Share

    October 2024
  97. CAO Z, Yao Y, Cai M, Zhang C, et al
    Blood markers for type-1,-2, and -3 inflammation are associated with severity of acutely decompensated cirrhosis.
    J Hepatol. 2024 Oct 25:S0168-8278(24)02649-7. doi: 10.1016/j.jhep.2024.
    >> Share

  98. NADIM MK, Kellum JA, Durand F
    Reply to correspondence on "Acute kidney Injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting".
    J Hepatol. 2024 Oct 23:S0168-8278(24)02646-1. doi: 10.1016/j.jhep.2024.
    >> Share

  99. LEE S, Arefaine B, Begum N, Stamouli M, et al
    Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial.
    J Hepatol. 2024 Oct 22:S0168-8278(24)02635-7. doi: 10.1016/j.jhep.2024.
    >> Share

  100. TALANIAN M, Almeqdadi M, Chen HH
    From dark bile to bright insight: A liver biopsy with advanced fibrosis and severe cholestasis.
    J Hepatol. 2024;81:e147-e150.
    >> Share

  101. TONON M, Barone A, Calvino V, Santori V, et al
    Reply to: correspondance on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
    J Hepatol. 2024;81:e170-e171.
    >> Share

  102. PAPATHEODORIDI M, De Ledinghen V, Lupsor-Platon M, Bronte F, et al
    Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
    J Hepatol. 2024;81:590-599.
    >> Share

  103. YOUNOSSI ZM, Kremer AE, Swain MG, Jones D, et al
    Assessment of fatigue and its impact in chronic liver disease.
    J Hepatol. 2024;81:726-742.
    >> Share

    September 2024
  104. LIN H, Cheuk-Fung Yip T, Lee HW, Meng X, et al
    AI-Safe-C Score: Assessing Liver-Related Event Risks in Non-Cirrhotic Patients after Successful Direct-Acting Antiviral Treatment.
    J Hepatol. 2024 Sep 20:S0168-8278(24)02560-1. doi: 10.1016/j.jhep.2024.
    >> Share

  105. XIAO G, Ren H
    A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?
    J Hepatol. 2024 Sep 19:S0168-8278(24)02556-X. doi: 10.1016/j.jhep.2024.
    >> Share

  106. DAJTI E, Villanueva C, Berzigotti A, Brujats A, et al
    Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: a post-hoc analysis of the PREDESCI trial.
    J Hepatol. 2024 Sep 18:S0168-8278(24)02553-4. doi: 10.1016/j.jhep.2024.
    >> Share

    August 2024
  107. TORRES S, El Maimouni C, Herrera G, Fernandez J, et al
    SPONTANEOUS CANDIDEMIA, A REAL INFECTION IN ADVANCED CIRRHOSIS.
    J Hepatol. 2024 Aug 30:S0168-8278(24)02499-1. doi: 10.1016/j.jhep.2024.
    >> Share

  108. LV Y, Wang Q, Luo B, Bai W, et al
    Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding: a prospective cohort study.
    J Hepatol. 2024 Aug 22:S0168-8278(24)02485-1. doi: 10.1016/j.jhep.2024.
    >> Share

  109. RAVANBAKHSH N, Genyk Y, Cheng A, Vats D, et al
    Biliary Cirrhosis associated with WDR19-Related Ciliopathy in Siblings.
    J Hepatol. 2024 Aug 18:S0168-8278(24)02475-9. doi: 10.1016/j.jhep.2024.
    >> Share

  110. YAO X, Song H, Shu H, Song J, et al
    Asymptomatic cirrhosis in a 35-year-old female.
    J Hepatol. 2024;81:e65-e67.
    >> Share

  111. TONON M, Barone A, Angeli P
    Reply to: Correspondence on "A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis".
    J Hepatol. 2024;81:e74-e75.
    >> Share

  112. CASTERA L, Garteiser P, Laouenan C, Vidal-Trecan T, et al
    Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    J Hepatol. 2024;81:195-206.
    >> Share

  113. DE HAAN J, Termorshuizen F, de Keizer N, Gommers D, et al
    One-year transplant-free survival following hospital discharge after ICU admission for ACLF in the Netherlands.
    J Hepatol. 2024;81:238-247.
    >> Share

    July 2024
  114. TONON M, Barone A, Angeli P
    Reply to: Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
    J Hepatol. 2024 Jul 29:S0168-8278(24)02434-6. doi: 10.1016/j.jhep.2024.
    >> Share

  115. DI COLA S, D'Amico G, Merli M
    Reply to "Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations ".
    J Hepatol. 2024 Jul 11:S0168-8278(24)02353-5. doi: 10.1016/j.jhep.2024.
    >> Share

  116. HE S, Luo Y, Ma W, Wang X, et al
    Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis.
    J Hepatol. 2024;81:135-148.
    >> Share

    June 2024
  117. MENDOZA YP, Tsouka S, Semmler G, Seubnooch P, et al
    Metabolic phenotyping of patients with Advanced Chronic Liver Disease for better characterization of Cirrhosis Regression.
    J Hepatol. 2024 Jun 27:S0168-8278(24)02334-1. doi: 10.1016/j.jhep.2024.
    >> Share

  118. ROONEY M, Duduskar SN, Ghait M, Reissing J, et al
    Type-I interferon shapes peritoneal immunity in cirrhosis and drives caspase-5-mediated progranulin release upon infection.
    J Hepatol. 2024 Jun 25:S0168-8278(24)02325-0. doi: 10.1016/j.jhep.2024.
    >> Share

  119. TARU V, Szabo G, Mehal W, Reiberger T, et al
    Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation.
    J Hepatol. 2024 Jun 20:S0168-8278(24)02322-5. doi: 10.1016/j.jhep.2024.
    >> Share

  120. SHAN D, Zhang G, Du Z
    Reevaluating Myosteatosis Criteria in Cirrhosis: Fluid and Gender Considerations.
    J Hepatol. 2024 Jun 9:S0168-8278(24)02309-2. doi: 10.1016/j.jhep.2024.
    >> Share

  121. LAWITZ EJ, Fraessdorf M, Neff GW, Schattenberg JM, et al
    Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
    J Hepatol. 2024 Jun 7:S0168-8278(24)02303-1. doi: 10.1016/j.jhep.2024.
    >> Share

  122. DAI H, Zhu C, Huai Q, Xu W, et al
    Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models.
    J Hepatol. 2024;80:913-927.
    >> Share

  123. WU XN, Wang MZ, Zhang N, Zhang W, et al
    Sex-determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology.
    J Hepatol. 2024;80:928-940.
    >> Share

  124. XU M, Warner C, Duan X, Cheng Z, et al
    HIV coinfection exacerbates HBV-induced liver fibrogenesis through a HIF-1alpha- and TGF-beta1-dependent pathway.
    J Hepatol. 2024;80:868-881.
    >> Share

    May 2024
  125. REIBERGER T, Lens S, Cabibbo G, Nahon P, et al
    EASL position paper on clinical follow-up after HCV cure.
    J Hepatol. 2024 May 30:S0168-8278(24)00275-7. doi: 10.1016/j.jhep.2024.
    >> Share

  126. MONTANO-LOZA AJ, Lytvyak E, Hirschfield G, Hansen BE, et al
    Prognostic Scores for Ursodeoxycholic Acid-Treated Patients Predict Graft Loss and Mortality in Recurrent Primary Biliary Cholangitis after Liver Transplantation.
    J Hepatol. 2024 May 29:S0168-8278(24)00345-3. doi: 10.1016/j.jhep.2024.
    >> Share

  127. ROY A, Tewari A, Sonthalia N, Chand Ghoshal U, et al
    Identifying Predictors of Acute and Non-acute Decompensation in a Cohort of MASLD Predominant Cirrhosis.
    J Hepatol. 2024 May 24:S0168-8278(24)00363-5. doi: 10.1016/j.jhep.2024.
    >> Share

  128. DI COLA S, D'Amico G, Caraceni P, Schepis F, et al
    Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
    J Hepatol. 2024 May 21:S0168-8278(24)00355-6. doi: 10.1016/j.jhep.2024.
    >> Share

  129. YANG M, Zhang F, Liu K
    Cirrhosis Decompensation: Clinical and Prognostic Analysis from a New Perspective.
    J Hepatol. 2024 May 9:S0168-8278(24)00337-4. doi: 10.1016/j.jhep.2024.
    >> Share

  130. ZHANG Y, Xiao F, Xie R
    Healthy volunteer bias for the role of genetic risk in dietary effects on hepatic steatosis, inflammation and fibrosis.
    J Hepatol. 2024 May 9:S0168-8278(24)00335-0. doi: 10.1016/j.jhep.2024.
    >> Share

  131. ANDREWS TS, Nakib D, Perciani CT, Ma XZ, et al
    Single-cell, single-nucleus, and spatial transcriptomics characterization of the immunological landscape in the healthy and PSC human liver.
    J Hepatol. 2024;80:730-743.
    >> Share

  132. XIAO H, Niu D, Zhang B
    Combined inhibition of Stat3 and periostin synergistically protects mice against liver fibrosis.
    J Hepatol. 2024;80:e207-e209.
    >> Share

    April 2024
  133. OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
    Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
    >> Share

  134. MCGETTIGAN B, Shah V
    EVERY SHERIFF NEEDS A DEPUTY: TARGETING NON-PARENCHYMAL CELLS TO TREAT HEPATIC FIBROSIS.
    J Hepatol. 2024 Apr 25:S0168-8278(24)00283-6. doi: 10.1016/j.jhep.2024.
    >> Share

  135. CHEN VL, Du X, Oliveri A, Chen Y, et al
    Genetic risk accentuates dietary effects on hepatic steatosis, inflammation and fibrosis in a population-based cohort.
    J Hepatol. 2024 Apr 4:S0168-8278(24)00230-7. doi: 10.1016/j.jhep.2024.
    >> Share

  136. KONDILI LA, Lazarus JV, Jepsen P, Murray F, et al
    Inequities in primary liver cancer in Europe: The state of play.
    J Hepatol. 2024;80:645-660.
    >> Share

    March 2024
  137. D'AMICO G, Perricone G
    Unaswered questions for non-acute (NAD) and acute (AD) decompensation in cirrhosis.
    J Hepatol. 2024 Mar 26:S0168-8278(24)00210-1. doi: 10.1016/j.jhep.2024.
    >> Share

  138. NADIM MK, Kellum JA, Forni L, Francoz C, et al
    Acute kidney injury in patients with Cirrhosis: Acute disease quality Initiative (ADQI) and international Club of ascites (ICA) joint multidisciplinary consensus meeting.
    J Hepatol. 2024 Mar 23:S0168-8278(24)00214-9. doi: 10.1016/j.jhep.2024.
    >> Share

  139. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.
    J Hepatol. 2024 Mar 21:S0168-8278(24)00198-3. doi: 10.1016/j.jhep.2024.
    >> Share

  140. YASHASWINI CN, Qin T, Bhattacharya D, Amor C, et al
    Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatotic liver disease.
    J Hepatol. 2024 Mar 18:S0168-8278(24)00197-1. doi: 10.1016/j.jhep.2024.
    >> Share

  141. MA AT, Sole C, Juanola A, Escude L, et al
    Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00157-0. doi: 10.1016/j.jhep.2024.
    >> Share

  142. JACHS M, Sandmann L, Hartl L, Tergast T, et al
    Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    J Hepatol. 2024 Mar 11:S0168-8278(24)00156-9. doi: 10.1016/j.jhep.2024.
    >> Share

  143. GE X, Desert R, Magdaleno F, Han H, et al
    Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
    J Hepatol. 2024;80:482-494.
    >> Share

  144. BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
    Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
    J Hepatol. 2024;80:467-481.
    >> Share

  145. LARRUE H, Bureau C, D'Amico G
    Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
    J Hepatol. 2024;80:e109-e110.
    >> Share

    February 2024
  146. CAON E, Martins M, Hodgetts H, Blanken L, et al
    Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
    J Hepatol. 2024 Feb 14:S0168-8278(24)00110-7. doi: 10.1016/j.jhep.2024.
    >> Share

  147. ARTRU F, Reiberger T
    One - or more - blind spot(s) unveiled in the new definition of decompensated cirrhosis.
    J Hepatol. 2024 Feb 8:S0168-8278(24)00118-1. doi: 10.1016/j.jhep.2024.
    >> Share

  148. HUANG CH, Tsai MH, Lin CY
    Identifying the pivotal role of non-acute decompensation as a precursor to acute decompensation in cirrhosis.
    J Hepatol. 2024 Feb 7:S0168-8278(24)00119-3. doi: 10.1016/j.jhep.2024.
    >> Share

  149. WARGNY M, Goronflot T, Rimbert A, Boursier J, et al
    Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population.
    J Hepatol. 2024 Feb 6:S0168-8278(24)00108-9. doi: 10.1016/j.jhep.2024.
    >> Share

  150. SILVA H, King JJ, Thorburn D, Luong TV, et al
    A rare cause of liver fibrosis in an adult patient.
    J Hepatol. 2024;80:e48-e50.
    >> Share

  151. LUO N, Zhang X, Huang J, Chen H, et al
    Prevalence of steatotic liver disease and associated fibrosis in the United States: Results from NHANES 2017-March 2020.
    J Hepatol. 2024;80:e70-e71.
    >> Share

    January 2024
  152. NING Z
    An in-depth exploration of new clinical and prognostic characteristics of decompensated liver cirrhosis patterns.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00104-1. doi: 10.1016/j.jhep.2024.
    >> Share

  153. CAMPION D, Caviglia GP, Alessandria C
    Reply to "The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis".
    J Hepatol. 2024 Jan 31:S0168-8278(24)00102-8. doi: 10.1016/j.jhep.2024.
    >> Share

  154. FAN X, Yang F, Zhou L, Yang L, et al
    Mycophenolate mofetil for the induction of remission in primary biliary cholangitis with predominant features of autoimmune hepatitis.
    J Hepatol. 2024 Jan 31:S0168-8278(24)00097-7. doi: 10.1016/j.jhep.2024.
    >> Share

  155. TANG R, Li Y, Chen R, Ma X, et al
    Reply to "ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort".
    J Hepatol. 2024 Jan 30:S0168-8278(24)00058-8. doi: 10.1016/j.jhep.2024.
    >> Share

  156. NAKANO M, Kawaguchi M, Kawaguchi T
    Almost Identical Values of Various Noninvasive Indexes for Hepatic Fibrosis and Steatosis between NAFLD and MASLD in Asia.
    J Hepatol. 2024 Jan 13:S0168-8278(24)00037-0. doi: 10.1016/j.jhep.2023.
    >> Share

  157. JACHS M, Hartl L, Simbrunner B, Semmler G, et al
    Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    J Hepatol. 2024 Jan 11:S0168-8278(24)00009-6. doi: 10.1016/j.jhep.2023.
    >> Share

  158. TERGAST TL, Maasoumy B
    The impact of infections on the onset of contrast-associated acute kidney injury in patients with cirrhosis.
    J Hepatol. 2024 Jan 3:S0168-8278(24)00001-1. doi: 10.1016/j.jhep.2023.
    >> Share

  159. BALCAR L, Mandorfer M, Hernandez-Gea V, Procopet B, et al
    Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving beta-blockers+ligation to prevent re-bleeding.
    J Hepatol. 2024;80:73-81.
    >> Share

    December 2023
  160. TONON M, D'Ambrosio R, Calvino V, Tosetti G, et al
    A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis.
    J Hepatol. 2023 Dec 16:S0168-8278(23)05359-X. doi: 10.1016/j.jhep.2023.
    >> Share

  161. VUKOTIC R, Di Donato R, Bosch J, Andreone P, et al
    Reply letter to the letter to the editor entitled: "5-mthf enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: a randomized placebo-controlled trial: was an accurate statistical analysis performed?".
    J Hepatol. 2023 Dec 12:S0168-8278(23)05302-3. doi: 10.1016/j.jhep.2023.
    >> Share

  162. NARDELLI S, Riggio O, Marra F, Gioia S, et al
    Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
    J Hepatol. 2023 Dec 12:S0168-8278(23)05310-2. doi: 10.1016/j.jhep.2023.
    >> Share

  163. RATZIU V, Harrison SA, Hajji Y, Magnanensi J, et al
    NIS2+(TM) as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
    J Hepatol. 2023 Dec 5:S0168-8278(23)05270-4. doi: 10.1016/j.jhep.2023.
    >> Share

  164. ZANETTO A, Senzolo M, Pelizzaro F, Mescoli C, et al
    A rare cause of painful hepatomegaly.
    J Hepatol. 2023;79:e228-e230.
    >> Share

  165. SIMON TG, Roelstraete B, Hagstrom H, Loomba R, et al
    Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
    J Hepatol. 2023;79:1366-1373.
    >> Share

    November 2023
  166. KRUK B, Liebe R, Weber SN, Milkiewicz P, et al
    ARID3A variant and the risk of primary biliary cholangitis in a Central European cohort.
    J Hepatol. 2023 Nov 28:S0168-8278(23)05290-X. doi: 10.1016/j.jhep.2023.
    >> Share

    October 2023
  167. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Corrigendum to "Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis" [J Hepatol 79(4) (2023 Oct) 967-976].
    J Hepatol. 2023 Oct 31:S0168-8278(23)05179-6. doi: 10.1016/j.jhep.2023.
    >> Share

  168. FERNANDEZ-GARZA LE
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. Was an accurate statistical analysis performed?
    J Hepatol. 2023 Oct 25:S0168-8278(23)05228-5. doi: 10.1016/j.jhep.2023.
    >> Share

  169. CAMPION D, Ponzo P, Risso A, Caropreso P, et al
    A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.
    J Hepatol. 2023 Oct 19:S0168-8278(23)05176-0. doi: 10.1016/j.jhep.2023.
    >> Share

  170. MURRAY SM, Pose E, Wittner M, Londono MC, et al
    Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and in liver transplant recipients.
    J Hepatol. 2023 Oct 18:S0168-8278(23)05174-7. doi: 10.1016/j.jhep.2023.
    >> Share

  171. MAIWALL R, Rao Pasupuleti SS, Sarin SK
    AUTHORS REPLY: High versus low target mean arterial pressure in septic shock in cirrhosis-A personalized TARGET-C approach may solve the conundrum!
    J Hepatol. 2023 Oct 13:S0168-8278(23)05144-9. doi: 10.1016/j.jhep.2023.
    >> Share

  172. CHEN X, Pan J, Zhu Y
    Anticoagulation for cirrhosis with portal vein thrombosis: Still a road to be explored.
    J Hepatol. 2023 Oct 11:S0168-8278(23)05163-2. doi: 10.1016/j.jhep.2023.
    >> Share

  173. CHE-TO LAI J, Lai-Hung Wong G, Cheuk-Fung Yip T
    Reply to "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?".
    J Hepatol. 2023 Oct 9:S0168-8278(23)05165-6. doi: 10.1016/j.jhep.2023.
    >> Share

  174. ABERG F, Savikko J, Eerola V, Nordin A, et al
    High prevalence of liver fibrosis and cirrhosis in a nationwide sample of organ donors with liver histology.
    J Hepatol. 2023 Oct 7:S0168-8278(23)05145-0. doi: 10.1016/j.jhep.2023.
    >> Share

  175. COLAPIETRO F, Maisonneuve P, Lytvyak E, Beuers U, et al
    Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
    J Hepatol. 2023 Oct 4:S0168-8278(23)05095-X. doi: 10.1016/j.jhep.2023.
    >> Share

    September 2023
  176. HERNAEZ R, Karvellas CJ, Liu Y, Sacleux SC, et al
    The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure.
    J Hepatol. 2023;79:717-727.
    >> Share

  177. BOURSIER J, Roux M, Sanyal AJ
    Reply to: "Agile scores are a good predictor of liver-related events in patients with NAFLD".
    J Hepatol. 2023;79:e128-e129.
    >> Share

  178. HARRISON SA, Ratziu V, Magnanensi J, Hajji Y, et al
    NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: A prospective derivation and validation study.
    J Hepatol. 2023;79:758-767.
    >> Share

  179. WONG VW, Ekstedt M, Wong GL, Hagstrom H, et al
    Changing epidemiology, global trends and implications for outcomes of NAFLD.
    J Hepatol. 2023;79:842-852.
    >> Share

  180. LIANG JX, Ampuero J, Niu H, Imajo K, et al
    An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
    J Hepatol. 2023;79:592-604.
    >> Share

  181. SHARMA N, Pandey S, Yadav M, Mathew B, et al
    Biomolecular map of albumin identifies signatures of severity and early mortality in acute liver failure.
    J Hepatol. 2023;79:677-691.
    >> Share

  182. PERON JM, Larrue H, Izopet J, Buti M, et al
    The pressing need for a global HEV vaccine.
    J Hepatol. 2023;79:876-880.
    >> Share

  183. NAKATSUKA T, Tateishi R, Sato M, Fujishiro M, et al
    Agile scores are a good predictor of liver-related events in patients with NAFLD.
    J Hepatol. 2023;79:e126-e127.
    >> Share

    August 2023
  184. EBRAHIMI F, Hagstrom H, Sun J, Bergman D, et al
    Familial Coaggregation of MASLD with Hepatocellular Carcinoma and Adverse Liver Outcomes: Nationwide Multigeneration Cohort Study.
    J Hepatol. 2023 Aug 28:S0168-8278(23)05071-7. doi: 10.1016/j.jhep.2023.
    >> Share

  185. BALLESTER MP, Carbonell-Asins JA, Balcar L, Reiberger T, et al
    Reply to: Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Aug 23:S0168-8278(23)05068-7. doi: 10.1016/j.jhep.2023.
    >> Share


  186. EASL Clinical Practice Guidelines on acute-on-chronic liver failure.
    J Hepatol. 2023;79:461-491.
    >> Share

  187. TSOCHATZIS EA
    Screening for liver fibrosis - sequential non-invasive testing works best.
    J Hepatol. 2023;79:263-265.
    >> Share

  188. KOTSILITI E, Leone V, Schuehle S, Govaere O, et al
    Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    J Hepatol. 2023;79:296-313.
    >> Share

  189. KJAERGAARD M, Lindvig KP, Thorhauge KH, Andersen P, et al
    Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    J Hepatol. 2023;79:277-286.
    >> Share

  190. TACKE F, Puengel T, Loomba R, Friedman SL, et al
    An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
    J Hepatol. 2023;79:552-566.
    >> Share

  191. DEVARBHAVI H, Asrani SK, Arab JP, Nartey YA, et al
    Global burden of liver disease: 2023 update.
    J Hepatol. 2023;79:516-537.
    >> Share

    July 2023
  192. PATIDAR KR, Belcher JM, Regner KR, St Hillien SA, et al
    Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04990-5. doi: 10.1016/j.jhep.2023.
    >> Share

  193. SANYAL AJ, Ratziu V, Loomba R, Anstee QM, et al
    Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis.
    J Hepatol. 2023 Jul 28:S0168-8278(23)04993-0. doi: 10.1016/j.jhep.2023.
    >> Share

  194. TAPPER EB, Bajaj JS
    Ammonia predicts clinical outcomes in cirrhosis - but there are caveats to consider.
    J Hepatol. 2023 Jul 27:S0168-8278(23)05003-1. doi: 10.1016/j.jhep.2023.
    >> Share

  195. VUKOTIC R, Di Donato R, Roncarati G, Simoni P, et al
    5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
    J Hepatol. 2023 Jul 21:S0168-8278(23)04940-1. doi: 10.1016/j.jhep.2023.
    >> Share

  196. AGARWAL B, Canizares RB, Saliba F, Ballester MP, et al
    Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure.
    J Hepatol. 2023;79:79-92.
    >> Share

  197. HACKSTEIN CP, Spitzer J, Symeonidis K, Horvatic H, et al
    Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury.
    J Hepatol. 2023;79:150-166.
    >> Share

  198. VILLANUEVA C, Torres F, Tripathi D, Bosch J, et al
    Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
    J Hepatol. 2023;79:e23-e24.
    >> Share

  199. SCHEINER B, Balcar L, Lisman T, Mandorfer M, et al
    Reply to: 'From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?'.
    J Hepatol. 2023;79:e27-e28.
    >> Share

  200. PONZIANI FR, Santopaolo F, Gasbarrini A, De Cristofaro R, et al
    From coagulation imbalance to prediction of advanced chronic liver disease decompensation: The wind of change?
    J Hepatol. 2023;79:e25-e27.
    >> Share

  201. RIDOLA L, Riggio O
    Comment to: "TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.".
    J Hepatol. 2023 Jul 1:S0168-8278(23)04938-3. doi: 10.1016/j.jhep.2023.
    >> Share

  202. LI Z, Hu Y, Zou B
    The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 cirrhotic patients.
    J Hepatol. 2023 Jul 1:S0168-8278(23)04935-8. doi: 10.1016/j.jhep.2023.
    >> Share

    June 2023
  203. AGRAWAL D, Ariga KK
    Target mean arterial pressure in critically ill cirrhotic patients with septic shock: More is not always better!
    J Hepatol. 2023 Jun 29:S0168-8278(23)04931-0. doi: 10.1016/j.jhep.2023.
    >> Share

  204. CASSANO SANTOS U, Coelho de Souza MDG, Ferreira da Motta Rezende G
    Selection of patients with portal hypertension and cirrhosis with real benefit of beta-blockers: still a current challenge.
    J Hepatol. 2023 Jun 26:S0168-8278(23)00428-2. doi: 10.1016/j.jhep.2023.
    >> Share

  205. NAYAGAM JS, Masson S, Ferguson JW, Griffiths W, et al
    Where does genetic testing fit in the diagnostic pathway of patients with cryptogenic cirrhosis?
    J Hepatol. 2023 Jun 26:S0168-8278(23)00429-4. doi: 10.1016/j.jhep.2023.
    >> Share

  206. ZHANG X, Sharma P, Maschmeyer P, Hu Y, et al
    GARP on hepatic stellate cells is essential for the development of liver fibrosis.
    J Hepatol. 2023 Jun 20:S0168-8278(23)00422-1. doi: 10.1016/j.jhep.2023.
    >> Share

  207. TAVABIE O
    Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.
    J Hepatol. 2023 Jun 12:S0168-8278(23)00413-0. doi: 10.1016/j.jhep.2023.
    >> Share

  208. LIM WH, Ng CH, Hao Tan DJ, Tseng M, et al
    Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    J Hepatol. 2023 Jun 10:S0168-8278(23)00412-9. doi: 10.1016/j.jhep.2023.
    >> Share

  209. ELKRIEF L, Ganne-Carrie N, Manceau H, Tanguy M, et al
    Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00401-4. doi: 10.1016/j.jhep.2023.
    >> Share

  210. LIU X, Wen X, Lu F
    Letter to the editor: For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?
    J Hepatol. 2023 Jun 9:S0168-8278(23)00402-6. doi: 10.1016/j.jhep.2023.
    >> Share

  211. SENZOLO M, Garcia-Pagan JC
    A major research gap: the use of anticoagulants in cirrhosis.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00407-5. doi: 10.1016/j.jhep.2023.
    >> Share

  212. FAN R, Chen L, Zhao S, Yang H, et al
    Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    J Hepatol. 2023 Jun 9:S0168-8278(23)00416-6. doi: 10.1016/j.jhep.2023.
    >> Share

  213. ALBILLOS A, Guerrero A, Tellez L
    Reply to: "Anticoagulation to prevent disease progression in patients with cirrhosis".
    J Hepatol. 2023 Jun 8:S0168-8278(23)00414-2. doi: 10.1016/j.jhep.2023.
    >> Share

  214. BALLESTER MP, Tranah TH, Balcar L, Fiorillo A, et al
    Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis.
    J Hepatol. 2023 Jun 3:S0168-8278(23)00351-3. doi: 10.1016/j.jhep.2023.
    >> Share

  215. ARTRU F, Goldberg D, Kamath PS
    Should patients with acute-on-chronic liver failure grade 3 receive higher priority for liver transplantation?
    J Hepatol. 2023;78:1118-1123.
    >> Share

  216. TANDON P, Zanetto A, Piano S, Heimbach JK, et al
    Liver transplantation in the patient with physical frailty.
    J Hepatol. 2023;78:1105-1117.
    >> Share

    May 2023
  217. INNES H, Nahon P
    Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions.
    J Hepatol. 2023 May 18:S0168-8278(23)00334-3. doi: 10.1016/j.jhep.2023.
    >> Share

  218. SHAWCROSS DL, Thabut D, Amodio P
    Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
    J Hepatol. 2023 May 11:S0168-8278(23)00327-6. doi: 10.1016/j.jhep.2023.
    >> Share

  219. LARRUE H, D'Amico G, Olivas P, Lv Y, et al
    TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
    J Hepatol. 2023 May 2:S0168-8278(23)00314-8. doi: 10.1016/j.jhep.2023.
    >> Share

  220. DI MARTINO V
    Methotrexate-induced liver fibrosis: The end of a long-held belief.
    J Hepatol. 2023;78:896-897.
    >> Share

  221. ATALLAH E, Grove JI, Crooks C, Burden-Teh E, et al
    Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.
    J Hepatol. 2023;78:989-997.
    >> Share

    April 2023
  222. MAIWALL R, Rao Pasupuleti SS, Hidam AK, Kumar A, et al
    A randomized-controlled trial (TARGET-C) of high vs. low target mean arterial pressure in patients with cirrhosis and septic shock.
    J Hepatol. 2023 Apr 21:S0168-8278(23)00229-5. doi: 10.1016/j.jhep.2023.
    >> Share

  223. ERIKSEN PL, Djernes L, Vilstrup H, Ott P, et al
    Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia targeting treatments.
    J Hepatol. 2023 Apr 13:S0168-8278(23)00220-9. doi: 10.1016/j.jhep.2023.
    >> Share

  224. JIN K, Shi Y, Zhang H, Zhangyuan G, et al
    A TNFalpha/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis.
    J Hepatol. 2023 Apr 9:S0168-8278(23)00215-5. doi: 10.1016/j.jhep.2023.
    >> Share

  225. VERMA N, Garg P, Bhardwaj A, Sarohi V, et al
    Candida leucine aminopeptidase: a novel mycoprotein linked to invasive candidiasis and mortality in acutely decompensated cirrhosis.
    J Hepatol. 2023 Apr 8:S0168-8278(23)00216-7. doi: 10.1016/j.jhep.2023.
    >> Share

    March 2023
  226. TOSETTI G, Degasperi E, Farina E, Primignani M, et al
    Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis?
    J Hepatol. 2023 Mar 30:S0168-8278(23)00203-9. doi: 10.1016/j.jhep.2023.
    >> Share

  227. LISMAN T, Bernal W, Luyendyk JP
    Anticoagulation to prevent disease progression in patients with cirrhosis.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00198-8. doi: 10.1016/j.jhep.2023.
    >> Share

  228. BAWEJA S, Kumari A, Negi P, Tomar A, et al
    Hepatopulmonay syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod.
    J Hepatol. 2023 Mar 28:S0168-8278(23)00192-7. doi: 10.1016/j.jhep.2023.
    >> Share

  229. MANGINI C, Gagliardi R, Causin F, Angeli P, et al
    Letter to the Editor: An isolated insular stroke mimics a bout of overt hepatic encephalopathy in a patient with cirrhosis.
    J Hepatol. 2023 Mar 19:S0168-8278(23)00179-4. doi: 10.1016/j.jhep.2023.
    >> Share

  230. VIOLI F, Pignatelli P, Cammisotto V
    Platelet defetcts in cirrhosis: fact or fiction?
    J Hepatol. 2023 Mar 8:S0168-8278(23)00173-3. doi: 10.1016/j.jhep.2023.
    >> Share

  231. BANTEL H, Schulze-Osthoff K
    Non-invasive tests for evaluating treatment response in NAFLD.
    J Hepatol. 2023;78:e101-e102.
    >> Share

  232. DURAND F, Kellum JA, Nadim MK
    Fluid Resuscitation in Patients with Cirrhosis and Sepsis: A Multidisciplinary Perspective.
    J Hepatol. 2023 Mar 1:S0168-8278(23)00113-7. doi: 10.1016/j.jhep.2023.
    >> Share

    February 2023
  233. GUERRERO A, Campo LD, Piscaglia F, Scheiner B, et al
    Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis.
    J Hepatol. 2023 Feb 27:S0168-8278(23)00112-5. doi: 10.1016/j.jhep.2023.
    >> Share

  234. SINGAL AG, Sanduzzi-Zamparelli M, Nahon P, Ronot M, et al
    International Liver cancer Association (ILCA) White Paper on Hepatocellular carcinoma Risk Stratification and Surveillance.
    J Hepatol. 2023 Feb 26:S0168-8278(23)00111-3. doi: 10.1016/j.jhep.2023.
    >> Share

  235. ZENG L, Li X, Peng Z
    Genetic variants improve hepatocellular carcinoma risk stratification, only in alcoholic cirrhosis patients?
    J Hepatol. 2023 Feb 22:S0168-8278(23)00102-2. doi: 10.1016/j.jhep.2023.
    >> Share

    January 2023
  236. TAO L, Yang G, Sun T, Tao J, et al
    Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in the liver via recruitment of SARM1.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00013-2. doi: 10.1016/j.jhep.2022.
    >> Share

  237. ANOLLI MP, Degasperi E, Allweiss L, Sangiovanni A, et al
    A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
    J Hepatol. 2023 Jan 3:S0168-8278(22)03475-4. doi: 10.1016/j.jhep.2022.
    >> Share

    December 2022
  238. SANYAL AJ, Williams SA, Lavine JE, Tetri B, et al
    Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in nonalcoholic fatty liver disease.
    J Hepatol. 2022 Dec 14:S0168-8278(22)03326-8. doi: 10.1016/j.jhep.2022.
    >> Share

  239. YIP TC, Wong VW, Lai MS, Lai JC, et al
    Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
    >> Share

    November 2022
  240. THABUT D, Kudo M
    Treatment of portal hypertension in patients with HCC at the era of Baveno VII.
    J Hepatol. 2022 Nov 29:S0168-8278(22)03313-X. doi: 10.1016/j.jhep.2022.
    >> Share

  241. LUO L, Yao X, Yang W
    Biejia-Ruangan compound and incidence of hepatocellular carcinoma.
    J Hepatol. 2022 Nov 16:S0168-8278(22)03305-0. doi: 10.1016/j.jhep.2022.
    >> Share

  242. ARTZNER T, Belli LS, Faitot F, Jalan R, et al
    Attitudes toward liver transplantation for ACLF-3 patients determine equity of access.
    J Hepatol. 2022 Nov 5. pii: S0168-8278(22)03286.
    >> Share

  243. RATZIU V, Harrison SA, Loustaud-Ratti V, Bureau C, et al
    Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
    J Hepatol. 2022 Nov 2. pii: S0168-8278(22)03160.
    >> Share

    October 2022
  244. PRYKE R, Guha IN
    Time to focus chronic liver diseases back into the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms.
    J Hepatol. 2022 Oct 22. pii: S0168-8278(22)03146.
    >> Share

    September 2022
  245. PATERNOSTRO R, Kwanten WJ, Reiberger T
    Portal hypertension is a key determinant of the risk for liver-related events in non-alcoholic fatty liver disease.
    J Hepatol. 2022 Sep 4. pii: S0168-8278(22)03062.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016